WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report—download today for expert insights, data, and a clear view of the U.S. dredging market.→ Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

30.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 957
Open 30.38
Bid (Size) 29.89 (200)
Ask (Size) 30.45 (100)
Prev. Close 30.38
Today's Range 30.38 - 30.38
52wk Range 4.300 - 40.37
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story ↗
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval ↗
On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval. 
Via Stocktwits
Topics Earnings

Performance

YTD
+7.3%
+7.3%
1 Month
-2.6%
-2.6%
3 Month
+20.6%
+20.6%
6 Month
+446.4%
+446.4%
1 Year
+327.3%
+327.3%

More News

Read More
News headline image
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval ↗
Via Stocktwits
Topics Earnings
News headline image
Capricor (CAPR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Capricor Therapeutics Inc (NASDAQ:CAPR) Reports Q4 2025 Loss, Focus Remains on FDA Review for Deramiocel ↗
Via Chartmill
News headline image
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy ↗
Via Stocktwits
News headline image
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures ↗
Via Stocktwits
News headline image
CAPR Stock Surged 17% Today — What’s Fueling The Rally? ↗
Via Stocktwits
News headline image
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains ↗
Via Stocktwits
News headline image
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On ↗
Via Stocktwits
News headline image
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
Via Stocktwits
News headline image
Here's Why This Biotechnology Skyrocketed by 439% in December ↗
Via The Motley Fool
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗
Via Stocktwits
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗
Via Stocktwits
News headline image
Why Did Capricor Therapeutics Stock Skyrocket Today? ↗
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Point To Steady Open: Why CAPR, MRVL, AEO, GTLB, CRWD Are On Traders' Radar ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout ↗
Via Stocktwits
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 30.38
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 05/08/26 04:00 PM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 1.39B
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.